アップデート
ライフサイエンスの発見のための AI を支えるモデルに関する視点と深掘り。
アップデート
This update enables computational biologists and medicinal chemists to rapidly predict 3D biomolecular structures and binding affinities through a streamlined workflow on Vecura, eliminating the need for complex, manual infrastructure setup.
アップデート
This update enables antibody researchers and protein engineers to streamline sequence analysis and design through a guided, no-code workflow on Vecura, eliminating the need to manage complex local model infrastructure.
アップデート
This update enables structural biologists and protein engineers to rapidly predict 3D protein structures through a streamlined workflow on Vecura, eliminating the need for complex MSA-based computational pipelines.
アップデート
Antibody researchers can now generate diverse, structurally-compatible antibody sequences directly within Vecura using the AntiDIF model, bypassing the need for complex local infrastructure setup.
アップデート
This update enables computational biologists and drug discovery researchers to predict protein-ligand binding poses and affinity directly through a guided workflow on Vecura, eliminating the need to manage complex, resource-intensive infrastructure.
アップデート
This update allows structural biologists and protein engineers to perform sophisticated all-atom protein complex design and folding directly within Vecura, eliminating the need to manage complex GPU-intensive infrastructure.
アップデート
This update enables researchers and drug discovery scientists to generate high-resolution 3D protein structures directly within the Vecura platform, streamlining structural biology workflows without the burden of managing complex computational infrastructure.
アップデート
This update empowers protein engineers and computational biologists to prioritize high-potential mutation candidates through a guided, zero-shot workflow on Vecura, eliminating the need for complex infrastructure or multiple-sequence alignment.
アップデート
This update enables protein engineers and computational biologists to design and score antibody and nanobody sequences through a guided, accessible workflow inside Vecura, eliminating the need for complex technical infrastructure.